Cytogenetic and therapeutic characterization of primary plasma cell leukemia: The IFM experience

Leukemia

Volumn 26, Issue 1, 2012, Pages 158-159

  Avet Loiseau, H ^a   Roussel, M ^b   Campion, L ^c   Leleu, X ^d   Marit, G ^e   Jardel, H ^f   Dib, M ^g   Decaux, O ^h   Lamy, T ^h   Tiab, M ^f   Cony Makhoul, P ^f   Banos, A ^f   Lepeu, G ^f   Lifermann, F ^f   MacRo, M ⁱ   Kolb, B ^j   Hulin, C ^k   Caillot, D ^l   Traulle, C ^m   Mathiot, C ⁿ   Royer, B ^o   more..

^a Team 12   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e University Hospital   (France)

^f NONE   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h RENNES UNIVERSITY HOSPITAL   (France)

ⁱ CAEN UNIVERSITY HOSPITAL   (France)

^j REIMS UNIVERSITY HOSPITAL   (France)

^k UNIVERSITY HOSPITAL OF NANCY   (France)

^l DIJON UNIVERSITY HOSPITAL   (France)

^m University Hospital   (France)

ⁿ INSTITUT CURIE   (France)

^o AMIENS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME 17P; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 4; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PRIMARY TUMOR; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 84856756871     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.176     Document Type: Letter

References (8)

1. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
2. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007; 109: 3489-3495. (Pubitemid 46572539)
3. Saccaro S, Fonseca R, Veillon DM, Cotelingam J, Nordberg ML, Bredeson C et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005; 78: 288-294. (Pubitemid 40471121)
4. Gertz M. Managing plasma cell leukemia. Leuk Lymphoma 2007; 48: 5-6. (Pubitemid 46978617)
5. Blade J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 1999; 13: 1259-1272. (Pubitemid 30017399)
6. Avet-Loiseau H, Daviet A, Brigaudeau C, Callet-Bauchu E, Terré C, Lafage-Pochitaloff M et al. Cytogenetic, interphase and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia. A study of 40 cases at diagnosis. Blood 2001; 97: 822-825.
7. Esparis-Ogando A, Alegre A, Aguado B, Mateo G, Gutiérrez N, Bladé J et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005; 114: 665-667. (Pubitemid 40349629)
8. Musto P, Rossini F, Gay F, Pitini V, Guglielmelli T, D'Arena G et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007; 109: 2285-2290. (Pubitemid 46801559)